https://aurealistherapeutics.com/aurealis-events/
Aurealis Events | Aurealis Therapeutics
Welcome to Aurealis Events! This is the place where you can learn everything about our upcoming events as well as our past events.
aurealiseventstherapeutics
https://aurealistherapeutics.com/partnering/
Partnering | Aurealis Therapeutics
Partnering with industry leaders to offer a breakthrough solution to massive unmet needs in chronic wounds, cancer and inflammation.
partneringaurealistherapeutics
https://aurealistherapeutics.com/work-with-us/
Work with us | Careers at Aurealis Therapeutics
Are you interested to join a team committed to the development of multi-target cell and gene therapies? In this page you can find our open positions.
us careersworkaurealistherapeutics
https://aurealistherapeutics.com/aurealis-news/aurealis-financing2024/
Aurealis Therapeutics Raises CHF 8 Million
Aurealis Therapeutics raises CHF 8 million to complete Phase 2 clinical studies in chronic wounds and accelerate oncology program.
aurealistherapeuticsraiseschfmillion
https://aurealistherapeutics.com/aurealis-news/swissbiotechday2025/
Aurealis Therapeutics to Attend Swiss Biotech Day 2025
Aurealis Therapeutics announced that COO Laurent Décory will attend Swiss Biotech Day 2025, taking place in Basel, Switzerland, from 5-6 May.
biotech dayaurealistherapeuticsattendswiss
https://aurealistherapeutics.com/diabetic-foot-ulcers/
Diabetic Foot Ulcers | Aurealis Therapeutics
AUP-16 is our lead product for chronic wounds: Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs) and Pressure Ulcer (PUs).
diabetic footulcersaurealistherapeutics
https://aurealistherapeutics.com/aurealis-events/wdsceurope2025/
World Drug Safety Congress Europe 2025 | Aurealis Therapeutics
Aurealis Therapeutics Drug Safety Officer, Matleena Piiroinen, will attend the World Drug Safety Congress Europe 2025 in Amsterdam.
drug safetycongress europeworldaurealistherapeutics
https://aurealistherapeutics.com/aurealis-events/lsxworldcongressusa2025/
LSX World Congress USA 2025 | Aurealis Therapeutics
Aurealis Therapeutics will be attending LSX World Congress USA, 16-17 September 2025 in Boston.
world congresslsxusaaurealistherapeutics
https://dev.aurethera.nucleargrafix.com/
Aurealis Therapeutics | Multi-target cell and gene therapies
Feb 5, 2024 - A game changer for chronic wounds, cancer, inflammatory diseases and beyond. Multi-target cell and gene therapies for unmet medical needs.
aurealistherapeuticsmultitargetcell
https://aurealistherapeutics.com/pipeline-and-science/
Pipeline and Science | Aurealis Therapeutics
Our product pipeline focuses on three cell and gene therapy areas: chronic wounds, cancer and inflammation. Learn about AUP-16 and AUP-55.
pipelinescienceaurealistherapeutics
https://aurealistherapeutics.com/cancer/
Cancer | Aurealis Therapeutics
AUP-55 is our lead pre-clinical candidate for ovarian cancer treatment; it enables survival in mouse ovarian cancer. Learn more about AUP-55.
canceraurealistherapeutics
https://aurealistherapeutics.com/aurealis-news/aurealis-therapeutics-appoints-hanna-lesch-as-cto/
Aurealis Therapeutics Appoints Hanna P. Lesch, PhD, as Chief Technology Officer
Aurealis Therapeutics a synthetic biology company developing breakthrough multi-targeting therapies announces the appointment of Hanna P. Lesch, PhD, as Chief...
chief technologyaurealistherapeuticsappointshanna
https://aurealisawards.org/
Aurealis Awards | Australia's premier speculative fiction awards
Australia's premier speculative fiction awards
aurealisawardsaustraliapremierspeculative
https://aurealistherapeutics.com/about/
About | Aurealis Therapeutics
Our mission is to develop curative therapies for chronic wounds, cancer and inflammatory diseases. Learn about our 4-in-1 platform and team.
aurealistherapeutics
https://aurealistherapeutics.com/aurealis-events/ewma2026/
EWMA 2026 Conference | Aurealis Therapeutics
Aurealis Therapeutics shared the results of its DIAMEND Phase 2 clinical trial of AUP-16 for non-healing DFUs at EWMA 2026.
ewmaconferenceaurealistherapeutics
https://aurealisawards.podbean.com/
Aurealis Awards: Behind the Curtain | aurealisawards
A series of interviews with key people behind the organisation and judging of the Aurealis Awards, in honour of its 30th birthday in 2025. Produced by...
aurealisawardsbehindcurtain
https://aurealistherapeutics.com/aurealis-news/ewma2025/
Aurealis Therapeutics largest participation to date at EWMA 2025
Aurealis participation highlighted exciting investigator data of DIAMEND Phase 2 DFU clinical trial presented by Prof. Alberto Piaggesi.
aurealistherapeuticslargestparticipationdate
https://aurealistherapeutics.com/chronic-wounds/
Chronic wounds | Aurealis Therapeutics
AUP-16 is our lead product for chronic wounds: diabetic foot ulcer, venous leg ulcer and pressure ulcer. Learn more about AUP-16.
chronicwoundsaurealistherapeutics
https://aurealistherapeutics.com/aurealis-news/aup-16-diamend-dfu-phase2-results/
Aurealis Therapeutics DIAMEND AUP-16 Phase-2 Final Results
Aurealis Therapeutics excellent final results of DIAMEND AUP-16 Phase 2 DFU clinical trial: complete wound closure rate tripled in chronic DFUs
aurealistherapeuticsaupphasefinal